ABPI comment on 2025 VPAG rates of 22.9%
The Voluntary Scheme for Branded Medicines Pricing and Access (VPAG) payment rate for newer medicines has been set at 22.9% in 2025, well above expectations, putting UK industry growth and investment…
Read the full articleYou might also wanna read
Analysis: UK-US pharmaceuticals trade deal could divert NHS funds and harm public health
Samuel Cross, Karl Claxton, and Andrew Hill argue that diversion of billions of NHS funding to pay more for new drugs under the UK-US trade
Analysis: UK-US pharmaceuticals trade deal could divert NHS funds and harm public health
Samuel Cross, Karl Claxton, and Andrew Hill argue that diversion of billions of NHS funding to pay more for new drugs under the UK-US trade

Pet prescriptions could be capped at £21 under proposed vet sector reforms
Ministers also considering licence requirement and regulator to try to cut bills and increase choice UK vets may have to have a licence and

Pet prescriptions could be capped at £21 under proposed vet sector reforms
Ministers also considering licence requirement and regulator to try to cut bills and increase choice UK vets may have to have a licence and

Pet prescriptions could be capped at £21 under proposed vet sector reforms
Ministers also considering licence requirement and regulator to try to cut bills and increase choice UK vets may have to have a licence and
Drugmakers Plan Price Increases on 350+ Medications Despite Government Pressure
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster
Study to Assess Effectiveness of Oral Atogepant in Adult Participants For Prevention of Migraine in the United Kingdom
Conditions : Migraine Sponsors : AbbVie Not yet recruiting
NHS trusts fail to account for over £400m in medical student training funds, BMJ investigation finds
Lack of transparency in how funding from NHS England for undergraduate medical training is spent suggests trusts are treating universities l
AbbVie, Trump Reach Drug Pricing Deal That Could Cut Costs for Older Americans
Breaking news: New deal between AbbVie and the Trump administration could reshape drug costs, tariffs, and how seniors buy medications in 20

Comments
Sign in to join the conversation.
No comments yet. Be the first.